Northwest Bio halts enrollment for glioblastoma vax PhIII trial; Germany grants €30 million to East African Community for vaccines, health supply chain management;

> Enrollment for Northwest Bio's ($NWBO) Phase III trial of DCVax for glioblastoma has temporarily halted so its investigators can submit new information for regulatory review. Release

> Germany granted €70 million ($79 million) to the East African Community, €30 million ($34 million) of which will fund vaccines and health supply chain management. More

> There hasn't been a poison ivy vaccine since the 1980s, which was discontinued because it didn't meet new FDA efficacy standards. But an allergist in Pennsylvania is working on a new vaccine, made with poison ivy extract and ethanol. Story

> Pakistan launched a new polio vaccine to accelerate its campaign to eradicate the disease by 2016. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.